



## Product information

- **Sample:** EDTA-plasma, finger prick whole blood.
- **Test principle:** immunological lateral-flow test for detecting GastroPanel biomarkers.
- **Kit components:** Plasma and venous whole blood kit: test cassette (pepsinogen I, pepsinogen II, gastrin-17, antibodies against *Helicobacter pylori*), sample diluent buffer instructions for use.
- **Fingerprick whole blood kit:** test cassette, safety lancet, fingerprick sampling device, predispensed sample diluent tubes, transfer pipette, test cassette (pepsinogen I, pepsinogen II, gastrin-17, antibodies against *Helicobacter pylori*), instructions for use.
- **Storage:** +2-30°C.
- **Speed:** results in 20 minutes.



Not available in the United States. In Japan for research use only. Check availability for other markets.

# GastroPanel® quick test NT



## Ordering details:

REF	Product
602410	GastroPanel® quick test NT, 30 tests For plasma and venous whole blood
602420	GastroPanel® quick test NT, 30 tests For fingerprick whole blood
740450	GP Reader NT Fluorescence Immunoanalyzer

## CONTACT

Biohit Oyj  
Laippatie 1  
00880 Helsinki  
Finland  
Tel. +358 9 773 861  
info@biohit.fi

Biohit HealthCare Srl  
Via Boncompagni, 3  
20139 Milano  
Italy  
Tel +39 02 38238113  
Fax +39 02 38236521  
info.italy@biohit.fi

Biohit HealthCare Ltd.  
Pioneer House, North Rd  
Ellesmere Port, CH65 1AD,  
United Kingdom  
Tel. +44 151 550 4 550  
Fax. +44 151 550 4 551  
info@biohithealthcare.co.uk

[biohithealthcare.com](http://biohithealthcare.com)

**BIOHIT**  
Innovating for Health

# GastroPanel® quick test NT

REVOLUTIONARY POINT-OF-CARE STOMACH HEALTH TEST



M100210en-02 © BIOHIT OYJ 08/2023

**BIOHIT**  
Innovating for Health

# GastroPanel® quick test NT

## GastroPanel® quick test NT for stomach health

GastroPanel quick test NT is the further development of the unique GastroPanel ELISA test. GastroPanel quick test NT allows fast diagnosis of and screening for *Helicobacter pylori*, atrophic gastritis with related risks as well as level of acid output of stomach in symptomatic and asymptomatic patients. The GastroPanel quick test NT speeds up the referral to further examinations. GastroPanel findings i) *H. pylori* infection, ii) atrophic gastritis or iii) high acid output are indications for gastroscopy and biopsy examination.

GastroPanel quick test NT is based on immunoassay method detecting GastroPanel biomarkers (pepsinogen I, pepsinogen II, gastrin-17, antibodies against *Helicobacter pylori*) from EDTA-plasma (1,2) and finger prick whole blood. GastroPanel quick test NT enables first-line diagnosis of dyspeptic patients and screening of both symptomatic and asymptomatic patients, easier than ever before.

*H. pylori*-induced or autoimmune type of atrophic gastritis increases the risk of gastric cancer as well as malabsorption of vitamin B12, calcium, iron, zinc and magnesium (1-11).

GastroPanel® quick test NT reduces costs, unnecessary clinical appointments and significantly improves the patient safety.

## Test procedure

1. Collect venous blood into an EDTA-tube. You may use the whole blood, or centrifuge the tube according to manufacturer's instructions to separate plasma. Make a dilution of 1:5 (80 µl of whole blood/plasma in 320 µl of diluent buffer).

Or A whole blood sample is collected from finger tip using safety lancet.

Collect fingerprick whole blood sample twice, each with a clean disposable sampling device (40 µl), and empty immediately into a dilution tube prefilled with 320 µl sample diluent buffer.

2. Transfer 80 µl of diluted sample into each of the sample windows.

3. Measure the cassette after 15 minutes with the GP reader NT.

4. The results and interpretation will be displayed on the screen.



## Literature

1. <https://www.biohithealthcare.com/additional-information>
2. Suovaniemi O. State of the art GastroPanel and Acetium innovations for the unmet need. <https://www.biohithealthcare.com/Scientific>.
3. <https://www.gastropanel.com/decision-makers/screening-model>
4. Varis K, Sipponen P, Laxén F, Samloff M, Huttunen JK, Taylor PR, Heinonen OP, Albanes D, Sande N, Virtamo J, Härkönen M & the Helsinki Gastritis Study Group. Implications of Serum Pepsinogen I in Early Endoscopic Diagnosis of Gastric Cancer and Dysplasia. *Scan J Gastroenterol* 2000;35:950-956.
5. Väänänen H, Vauhkonen M, Helske T, Kääriäinen I, Rasmussen M, Tunturi-Hihnala H, Koskenpato J, Sotka M, Turunen M, Sandström R, Ristikankare M, Jussila A, Sipponen P. Non-Endoscopic Diagnosis of Atrophic Gastritis with a Blood Test. Correlation between Gastric Histology and Serum Levels of Gastrin-17 and Pepsinogen I. *A Multicentre Study. Eur J Gastroenterol Hepatol* 2003; 15: 885-891.
6. Sipponen P, Graham DY. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. *Scand. J. Gastroenterol.* 2007;42 (1);2-10.
7. Storskrubb T, Aro P, Ronkainen J, Sipponen P, Nyhlin H, Talley NJ, Engstrand L, Stolte M, Vieth M, Walker M and Agrés L. Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. *Scand J Gastroenterol*, 2008; 43:1448-1455.
8. Agrés L, Kuipers EJ, Kupcinkas L, Malfertheiner P, Di Mario F, Leja M, Mahachai V, Yaron N, van Oijen M, Perez Perez G, Rugge M, Ronkainen J, Salaspuuro M, Sipponen P, Sugano K, Sung J. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers, *Scandinavian Journal of Gastroenterology* 2012; 47: 136-147
9. Syrjänen K. Role of serological biomarker testing (GastroPanel®) in diagnosis of symptomatic dyspepsia and in screening of the risks of stomach cancer. *EC Gastroenterol Digest Syst* 2017;1(6):209-222.
10. Syrjänen, K., Eskelinen, M., Peetsalu, A., Sillakivi, T., Sipponen, P., Härkönen, M., Paloheimo, L., Mäki, M., Tiusanen, T., Suovaniemi, O., DiMario, F. and Fan, ZP. GastroPanel® Biomarker Panel: The most comprehensive test for *Helicobacter pylori* infection and its clinical sequelae. A critical review. *Anticancer Res.* 2019;39:1091-1104.
11. Vohlonen I, Pukkala E, Malila N, Härkönen M, Hakama M, Koistinen V, Sipponen P. (2016) Risk of gastric cancer in *Helicobacter pylori* infection in a 15-year follow-up, *Scandinavian Journal of Gastroenterology*, 51:10, 1159-1164, DOI:10.1080/00365521.2016.1183225, <http://dx.doi.org/10.1080/00365521.2016.1183225>